ClinicalTrials.gg
Sign In
RecruitingNCT04405856Updated May 28, 2020

Outcome of Patients Treated With IABP

An observational study in Acute Coronary Syndrome, Cardiogenic Shock and Coronary Artery Disease, sponsored by Nanjing Medical University. Recruiting at 1 site in China. Open to participants aged 1 Year to 100 Years. Per ClinicalTrials.gov, last updated 2020-05-28.

Sponsored by Nanjing Medical University · Observational

From the registry’s dates

  • Primary completion was expected by Dec 2025, 10 months ago, but the record still lists the study as recruiting.
  • Started Feb 2012; still recruiting 14 years 9 months later.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
1,000
Ages
1 Year to 100 Years
Sex
All
01

Study summary

Intra-Aortic Balloon Pumps (IABP) is a widely used and effective left ventricular adjuvant therapy. IABP is an inflatable device placed in the aorta that inflates with diastole and deflates with systole. The aim of this study is to investigate the outcome of patients treated With IABP, and to evaluate the short-term and long-term outcomes of patients with IABP.

02

Conditions studied

  • Acute Coronary Syndrome
  • Cardiogenic Shock
  • Coronary Artery Disease
  • Heart Failure
  • Left Ventricular Dysfunction
  • Low Cardiac Output Syndrome
  • Post-cardiac Surgery
03

In context

Acute Coronary Syndrome

1,488 studies on the registry are indexed under Acute Coronary Syndrome; 273 are open to participants now.

This study's planned enrollment of 1,000 is above the median of 500 across 590 observational studies indexed under Acute Coronary Syndrome.

Browse Acute Coronary Syndrome studies →

Lead sponsor

Nanjing Medical University is the lead sponsor of 171 studies on the registry; 52 are open to participants now.

Browse Nanjing Medical University studies →

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
1 Year to 100 Years
Sexes eligible
All
Sampling method
Non-probability sample

Study population

Patients receiving IABP for circulatory support

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients receiving IABP for circulatory support

Exclusion criteria

Exclusion Criteria:

  • Refusal of consent
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
1,000 participants (estimated)
Patient registry
No

Interventions

  • DeviceIntra Aortic Balloon Pump

    Intra Aortic Balloon Pump (IABP) is a circulatory mechanical support device, placed in descending aorta, distally from left subclavian artery and proximally from renal artery. IABP works with counterpulsation concept, synchronized with heart cycle.

06

What researchers measure

Primary outcomes

  1. All-cause mortality

    Time frame: 30 days after IABP implantation

Secondary outcomes

  1. All-cause mortality

    Time frame: 3 months after IABP implantation

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2012 (actual). Primary completion is estimated for Dec 2025, 166 months after the start.

Of 243 non-industry observational studies under Acute Coronary Syndrome, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 71. This study's planned 166 months is above that.

Counting every sponsor, half of 277 studies reached it within 35 months; a quarter within 18 and three quarters within 68.

How these figures are worked out, and which studies are left out of them.

Registered
May 26, 2020
First posted
May 28, 2020
StartActual
Feb 1, 2012
Primary completionEst.
Dec 31, 2025
CompletionEst.
Dec 31, 2025
Last update
May 28, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 28, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04405856
Lead sponsor
Nanjing Medical University
Responsible party
Hong Liu (Investigator of Department of Cardiac Surgery, Nanjing Medical University) — Principal investigator
First posted
May 28, 2020
Start date
Feb 1, 2012
Primary completion
Dec 31, 2025 (estimated)
Completion
Dec 31, 2025 (estimated)
Last update
May 28, 2020

Study contacts

Hong Liu, MD
Contact
DR.HONGLIU@FOXMAIL.COM
18801281613
Yong-feng Shao, MD
Contact
yfshaojph@sina.com
02568303100
Yong-feng Shao, MD
study director · The First Affiliated Hospital with Nanjing Medical University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Acute Coronary Syndrome →

Other studies from this sponsor

Nanjing Medical University →

Start the discussion